Discovery of novel triazole compounds as selective IL-1β releasement inhibitors
Inflammation and immunity are closely related to the occurrence and development of a variety of immune diseases. Although IL-1β has been identified as a key cytokine in many immune diseases, safe and specific small molecular IL-1β releasement inhibitors a
Inflamsome nucleotide binding oligomerization domain-like receptor protein 3 inhibitor as well as preparation method and application thereof
The invention discloses compounds which are shown in a formula I and can inhibit secretion of inflammasome nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3) and secretion of interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), and a preparation method of the compound. ELISA experiments show that the compounds can significantly inhibit the activity of NLRP3 and reduce the expression of NLRP3 downstream inflammatory factors IL-1beta. A further experiment shows that part of the compounds have a selective inhibition effect on IL-1beta/TNF-alpha. The compounds shown in the formula I are expected to become novel anti-inflammatory drugs and autoimmune disease treatment drugs.
-
Paragraph 0112-0114; 0151-0153
(2021/11/03)
More Articles about upstream products of 154087-05-5